We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Pfizer/Flynn Pharma and excessive pricing - a case study

David Hull discusses the implications of Pfizer/Flynn Pharma's successful appeal against a 2016 ruling of excessive pricing.


David Hull

Van Bael & Bellis
David Hull
  • Posted 30 November 2018
  • Duration 5:48 min
  • Language English